Pharmaceuticals & Drugs

COHANCE

Cohance Lifesciences Ltd.

Caution — weak structure

Late Stage
VCP active

Setup readiness

Late Stage

Pivot Levels
₹512.3-517.5
Support Level
₹478.6
Resistance
₹617.9
Risk Distance
7.5% to stop

Reference levels for educational study only. Not a recommendation to buy or sell.

RS
44.0
ADX
32.0
Vol
20.0

Swing Edge Intelligence

Structured setup analysis · research only

Setup status · Weak structure

Stage 3 trend context — relative strength and breakout quality remain primary constraints.

Relative strength Weak
Breakout readiness Low
Accumulation Constructive

Bullish factors

  • Price trades below the long-term trend anchor (200DMA).
  • Relative strength remains below leadership thresholds.
  • Still materially below prior highs, which limits momentum quality.
  • Trend stage reads as Stage 3 — not in a classic Stage 2 advance.
  • 1 prior pivot rejection in last 60d (-8 pts).
  • ATR 4.2%/day — healthy volatility (+4).
  • BB squeeze — energy building.
  • MACD positive and rising — confirmation only (no bonus).
  • RSI 62 — ideal setup zone.
  • OBV divergence — price flat, volume rising: hidden strength.
  • Recent volume expansion — institutional participation may be returning.
  • Volume flow suggests quiet institutional accumulation.

Risk factors

  • Price up but OBV diverging — demand weakening
  • Not in a Stage 2 uptrend (Stage 3)

Overall view

Short-term accumulation is visible, though it should be weighed against trend and RS context. Overall setup quality remains limited despite any localized compression or accumulation cues.

Size this trade

Setup research

COHANCE — trend, RS & risk snapshot (not a trade recommendation)

Signal · context · invalidation · risk · skip reasons — research only

Positives

Building toward the pivot (11% below)

Flagged today

Context & regime

  • Market regime Mixed / range-bound
  • Trend stage Stage 3 — caution
  • Sector Mid-pack (#20/40)
  • Relative strength Lagging (RS 44)
  • Trend strength Strong (ADX 32)

Negatives

This idea is wrong below ₹478.6 (-4.5% away)

Base / stop support breaks — the swing thesis is wrong below here

  • Stop / base low₹478.6
  • Pivot — failure re-entry below₹514.9

Risk distance

7.5% to stop
1.8× ATR
2.6× R:R
19.4% reward

Risk ≈ ₹38.92/share from entry ₹517.5.

Reasons to skip 2

Disqualifiers that apply even if the score looks good.

  • Price up but OBV diverging — demand weakening
  • Not in a Stage 2 uptrend (Stage 3)
Setup metrics Latest scan

COHANCE Technical Analysis & Swing Setup

Grouped structure, momentum and risk from the latest research scan.

Volume Profile bearish
POC₹465.48
VAH₹514.9
VAL₹377.87
Vol above POC30.2%
Institutional Activity — Heavy Accumulation
Avg cost basis₹432.07
Acc zone₹318.9–514.9
Accumulation Sessions3
CMF0.12

Structure

Trend / stage
Stage 3
Base
Weekly trend
Above 30-wk MA (flat)
Above 30W
RS rank
44.0
Weakening
ADX
32.0
Strong

Momentum

RSI
62.0
Strong
Recent move (10d / 20d)
+8.2% / +6.8%
Neutral
Volume quality
20.0
Thin
Relative strength
Lagging
Neutral

Risk

Failure risk
46.0
Moderate
ATR % / day
4.2%
Healthy
Distribution
0 day(s)
Accumulation
Volatility
8 VCP
Contracting
More scanner fields
Sector RS 0.0%
Base 16w · 48.2%
VCP waves 8x
Vol dry-up No
Avg value ₹184.2 Cr
Failure flags Overhead supply, RS laggard, Deep base

COHANCE Support & Resistance Levels

AI insights

AI Insights

Generated with AI

These insights are AI-generated to support your research process and should not be treated as investment advice or a recommendation to buy or sell securities.

Sign in to unlock AI Insights

Personalised swing trade analysis powered by Gemini AI

Pattern context 52w · setup · flow

52-week range

Stage-2 ideal band  ·  Early recovery

Pattern highlights

Loading…

Pattern signals from the latest scan

Smart money flow

Last 60 sessions · accumulation vs distribution

Loading…
Session flow 60 trading days
OBV trend On-balance volume · same window
·
Accumulation Distribution Neutral
Setup intelligence Overhead · VCP · radar · risk

Overhead supply

Resistance ceiling above current price

Loading…

Chase / failure risk

Honest read on exhaustion & extended moves

Loading…

Base / VCP coil

Depth, contractions & pivot distance

Loading…

Setup quality radar

Shape of the setup in one view

Loading…
Peer comparison Sector peers

Sector Peer Comparison

Loading sector peers…

Fetching peer data…
COHANCE FAQ Common swing-trading questions

Frequently asked questions about COHANCE

What are the screener observations for COHANCE?

On Swing Edge's swing-setup framework, Cohance Lifesciences Ltd. (COHANCE) currently grades C — mixed — needs patience. Building toward the pivot (11% below). Flagged today. This is educational research, not investment advice.

What are COHANCE's support and resistance levels?

For COHANCE, near-term support sits around ₹478.6 (the base/stop zone); overhead resistance is around ₹514.9 (the breakout pivot); the next resistance above is ₹617.9. This is educational research, not investment advice.

What is the breakout / pivot level for COHANCE?

The breakout pivot for COHANCE is around ₹514.9. Price is about 11.0% below the pivot and still building toward it. A breakout is typically confirmed on a close above the pivot with above-average volume. This is educational research, not investment advice.

Is COHANCE above its 50-day and 200-day moving averages?

COHANCE is currently in Stage 3, not a confirmed Stage 2 uptrend, so trend support from the key moving averages is weaker than ideal for a swing entry. This is educational research, not investment advice.

How strong is COHANCE versus the market (RS rank)?

COHANCE has a relative strength (RS) rank of 44 out of 100 versus the NSE universe, making it lagging the broader market on relative strength. Trend strength (ADX) reads 32, indicating a strong trend. This is educational research, not investment advice.

Answers are generated from Swing Edge's latest scan data and are for research only — not investment advice.

Prices and day-change figures use the last daily close from scan data dated 2026-06-25 — not live intraday NSE quotes.